Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Ophthalmology and Therapy
Published in: Ophthalmology and Therapy 1/2018

Open Access 01-06-2018 | Review

The Role of Diet in Glaucoma: A Review of the Current Evidence

Authors: Adi M. Al Owaifeer, Abdulaziz A. Al Taisan

Published in: Ophthalmology and Therapy | Issue 1/2018

Login to get access

Abstract

Intraocular pressure (IOP) reduction by medications, laser, or surgery remains the mainstay of treatment in glaucoma. However, the role of complementary and alternative medicine (CAM) in glaucoma has received great interest from both patients and ophthalmologists. Previous evidence suggests that diet, a major domain of CAM, can influence an individual’s IOP level. Furthermore, certain dietary components have been linked to the incidence and progression of glaucoma. In this review, we aim to provide a summary of the current evidence regarding the role of obesity, certain dietary components, and dietary supplements in glaucoma.
Literature
1.
Pascolini D, Mariotti SP. Global estimates of visual impairment: 2010. Br J Ophthalmol. 2012;96(5):614–8.CrossRefPubMed
2.
Coleman AL, Miglior S. Risk factors for glaucoma onset and progression. Surv Ophthalmol. 2008;53(Suppl 1):S3–10.CrossRefPubMed
3.
Flammer J, Haefliger IO, Orgül S, Resink T. Vascular dysregulation: a principal risk factor for glaucomatous damage? J Glaucoma. 1999;8(3):212–9.CrossRefPubMed
4.
Izzotti A, Bagnis A, Saccà SC. The role of oxidative stress in glaucoma. Mutat Res. 2006;612(2):105–14.CrossRefPubMed
5.
Rieck J. The pathogenesis of glaucoma in the interplay with the immune system. Invest Ophthalmol Vis Sci. 2013;54(3):2393–409.CrossRefPubMed
6.
Casson RJ. Possible role of excitotoxicity in the pathogenesis of glaucoma. Clin Experiment Ophthalmol. 2006;34(1):54–63.CrossRefPubMed
7.
Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120(10):1268–79.CrossRefPubMed
8.
Osborne NN. Recent clinical findings with memantine should not mean that the idea of neuroprotection in glaucoma is abandoned. Acta Ophthalmol. 2009;87(4):450–4.CrossRef
9.
Klöcker N, Kermer P, Weishaupt JH, Labes M, Ankerhold R, Bähr M. Brain-derived neurotrophic factor-mediated neuroprotection of adult rat retinal ganglion cells in vivo does not exclusively depend on phosphatidyl-inositol-3′-kinase/protein kinase B signaling. J Neurosci. 2000;20(18):6962–7.CrossRefPubMed
10.
Yamamoto R, Yoneda S, Hara H. Neuroprotective effects of beta-secretase inhibitors against rat retinal ganglion cell death. Neurosci Lett. 2004;370(1):61–4.CrossRefPubMed
11.
Kojima S, Sugiyama T, Kojima M, Azuma I, Ito S. Effect of the consumption of ethanol on the microcirculation of the human optic nerve head in the acute phase. Jpn J Ophthalmol. 2000;44(3):318–9.CrossRefPubMed
12.
Jia LY, Sun L, Fan DS, Lam DS, Pang CP, Yam GH. Effect of topical Ginkgo biloba extract on steroid-induced changes in the trabecular meshwork and intraocular pressure. Arch Ophthalmol. 2008;126(12):1700–6.CrossRefPubMed
13.
Patel S, Mathan JJ, Vaghefi E, Braakhuis AJ. The effect of flavonoids on visual function in patients with glaucoma or ocular hypertension: a systematic review and meta-analysis. Graefes Arch Clin Exp Ophthalmol. 2015;253(11):1841–50.CrossRefPubMed
14.
Bower TN, Muhsen S, Overbury O, Birt C, Kasner O. Canadian ophthalmologists’ opinions concerning complementary and alternative medicine (CAM) use in glaucoma. J Glaucoma. 2014;23(7):430–4.CrossRefPubMed
15.
Rhee DJ, Spaeth GL, Myers JS, et al. Prevalence of the use of complementary and alternative medicine for glaucoma. Ophthalmology. 2002;109(3):438–43.CrossRefPubMed
16.
Wan MJ, Daniel S, Kassam F, et al. Survey of complementary and alternative medicine use in glaucoma patients. J Glaucoma. 2012;21(2):79–82.PubMed
17.
Ajayi OB, Ukwade MT. Caffeine and intraocular pressure in a Nigerian population. J Glaucoma. 2001;10(1):25–31.CrossRefPubMed
18.
Giaconi JA, Yu F, Stone KL, et al. The association of consumption of fruits/vegetables with decreased risk of glaucoma among older African-American women in the study of osteoporotic fractures. Am J Ophthalmol. 2012;154(4):635–44.CrossRefPubMedPubMedCentral
19.
Lee J, Sohn SW, Kee C. Effect of Ginkgo biloba extract on visual field progression in normal tension glaucoma. J Glaucoma. 2013;22(9):780–4.CrossRefPubMed
20.
Kim HT, Kim JM, Kim JH, et al. Relationships between anthropometric measurements and intraocular pressure: the Korea National Health and Nutrition Examination Survey. Am J Ophthalmol. 2017;173:23–33.CrossRefPubMed
21.
Lin CP, Lin YS, Wu SC, Ko YS. Age- and gender-specific association between intraocular pressure and metabolic variables in a Taiwanese population. Eur J Intern Med. 2012;23(1):76–82.CrossRefPubMed
22.
Cohen E, Kramer M, Shochat T, Goldberg E, Garty M, Krause I. Relationship between body mass index and intraocular pressure in men and women: a population-based study. J Glaucoma. 2016;25(5):e509–13.CrossRef
23.
Yoshida M, Ishikawa M, Karita K, et al. Association of blood pressure and body mass index with intraocular pressure in middle-aged and older Japanese residents: a cross-sectional and longitudinal study. Acta Med Okayama. 2014;68(1):27–34.PubMed
24.
Wang YX, Xu L, Zhang XH, You QS, Zhao L, Jonas JB. Five-year change in intraocular pressure associated with changes in arterial blood pressure and body mass index. The Beijing eye study. PLoS One. 2013;8(10):e77180.CrossRefPubMedPubMedCentral
25.
Nakano T, Tatemichi M, Miura Y, Sugita M, Kitahara K. Long-term physiologic changes of intraocular pressure: a 10-year longitudinal analysis in young and middle-aged Japanese men. Ophthalmology. 2005;112(4):609–16.CrossRefPubMed
26.
27.
Caballero M, Liton PB, Epstein DL, Gonzalez P. Proteasome inhibition by chronic oxidative stress in human trabecular meshwork cells. Biochem Biophys Res Commun. 2003;308(2):346–52.CrossRefPubMed
28.
Stojanov O, Stokić E, Sveljo O, Naumović N. The influence of retrobulbar adipose tissue volume upon intraocular pressure in obesity. Vojnosanit Pregl. 2013;70(5):469–76.CrossRefPubMed
29.
Çekiç B, Toslak İE, Doğan B, Çakır T, Erol MK, Bülbüller N. Effects of obesity on retrobulbar flow hemodynamics: color Doppler ultrasound evaluation. Arq Bras Oftalmol. 2017;80(3):143–7.CrossRefPubMed
30.
Kim YK, Choi HJ, Jeoung JW, Park KH, Kim DM. Five-year incidence of primary open-angle glaucoma and rate of progression in health center-based Korean population: the Gangnam Eye Study. PLoS One. 2014;9(12):e114058.CrossRefPubMedPubMedCentral
31.
Le A, Mukesh BN, Mccarty CA, Taylor HR. Risk factors associated with the incidence of open-angle glaucoma: the visual impairment project. Invest Ophthalmol Vis Sci. 2003;44(9):3783–9.CrossRefPubMed
32.
Jiang X, Varma R, Wu S, et al. Baseline risk factors that predict the development of open-angle glaucoma in a population: the Los Angeles Latino Eye Study. Ophthalmology. 2012;119(11):2245–53.CrossRefPubMedPubMedCentral
33.
Ramdas WD, Wolfs RC, Hofman A, De Jong PT, Vingerling JR, Jansoniusg NM. Lifestyle and risk of developing open-angle glaucoma: the Rotterdam study. Arch Ophthalmol. 2011;129(6):767–72.CrossRefPubMed
34.
Pasquale LR, Willett WC, Rosner BA, Kang JH. Anthropometric measures and their relation to incident primary open-angle glaucoma. Ophthalmology. 2010;117(8):1521–9.CrossRefPubMedPubMedCentral
35.
Leske MC, Connell AM, Wu SY, Hyman LG, Schachat AP. Risk factors for open-angle glaucoma. The Barbados Eye Study. Arch Ophthalmol. 1995;113(7):918–24.CrossRefPubMed
36.
Jang HD, Kim DH, Han K, et al. Relationship between Intraocular pressure and parameters of obesity in Korean Adults: the 2008–2010 Korea National Health and Nutrition Examination Survey. Curr Eye Res. 2015;40(10):1008–17.CrossRefPubMed
37.
Zhao D, Kim MH, Pastor-Barriuso R, et al. A longitudinal study of association between adiposity markers and intraocular pressure: the Kangbuk Samsung Health Study. PLoS One. 2016;11(1):e0146057.CrossRefPubMedPubMedCentral
38.
Wygnanski-Jaffe T, Bieran I, Tekes-Manova D, Morad Y, Ashkenazi I, Mezer E. Metabolic syndrome: a risk factor for high intraocular pressure in the Israeli population. Int J Ophthalmol. 2015;8(2):403–6.PubMedPubMedCentral
39.
Oh SW, Lee S, Park C, Kim DJ. Elevated intraocular pressure is associated with insulin resistance and metabolic syndrome. Diabetes Metab Res Rev. 2005;21(5):434–40.CrossRefPubMed
40.
Newman-casey PA, Talwar N, Nan B, Musch DC, Stein JD. The relationship between components of metabolic syndrome and open-angle glaucoma. Ophthalmology. 2011;118(7):1318–26.PubMedPubMedCentral
41.
Giurlani BP, Obie LG, Petersen CG, Presley DD. Alcohol and open angle glaucoma–influence on detection, IOP, BP/IOP ratios. J Am Opt Assoc. 1978;49(4):409–16.
42.
Buckingham T, Young R. The rise and fall of intra-ocular pressure: the influence of physiological factors. Ophthalmic Physiol Opt. 1986;6(1):95–9.CrossRefPubMed
43.
Houle RE, Grant WM. Alcohol, vasopressin, and intraocular pressure. Invest Ophthalmol. 1967;6(2):145–54.PubMed
44.
Leydhecker W, Krieglstein GK, Uhlich E. Experimental investigations on the mode of action of alcoholic liquor on the intra-ocular pressure (author’s transl). Klin Monbl Augenheilkd. 1978;173(1):75–9.PubMed
45.
Kojima S, Sugiyama T, Kojima M, Azuma I, Ito S. Effect of the consumption of ethanol on the microcirculation of the human optic nerve head in the acute phase. Jpn J Ophthalmol. 2000;44(3):318–9.CrossRefPubMed
46.
Klein BE, Klein R, Ritter LL. Relationship of drinking alcohol and smoking to prevalence of open-angle glaucoma. The Beaver Dam Eye Study. Ophthalmology. 1993;100(11):1609–13.CrossRefPubMed
47.
Kang JH, Willett WC, Rosner BA, Hankinson SE, Pasquale LR. Prospective study of alcohol consumption and the risk of primary open-angle glaucoma. Ophthalmic Epidemiol. 2007;14(3):141–7.CrossRefPubMed
48.
Xu L, You QS, Jonas JB. Prevalence of alcohol consumption and risk of ocular diseases in a general population: the Beijing Eye Study. Ophthalmology. 2009;116(10):1872–9.CrossRefPubMed
49.
Kahn HA, Milton RC. Alternative definitions of open-angle glaucoma. Effect on prevalence and associations in the Framingham eye study. Arch Ophthalmol. 1980;98(12):2172–7.CrossRefPubMed
50.
Fan BJ, Leung YF, Wang N, et al. Genetic and environmental risk factors for primary open-angle glaucoma. Chin Med J. 2004;117(5):706–10.PubMed
51.
Seddon JM, Schwartz B, Flowerdew G. Case-control study of ocular hypertension. Arch Ophthalmol. 1983;101(6):891–4.CrossRefPubMed
52.
Jiwani AZ, Rhee DJ, Brauner SC, et al. Effects of caffeinated coffee consumption on intraocular pressure, ocular perfusion pressure, and ocular pulse amplitude: a randomized controlled trial. Eye (Lond). 2012;26(8):1122–30.CrossRefPubMedPubMedCentral
53.
Avisar R, Avisar E, Weinberger D. Effect of coffee consumption on intraocular pressure. Ann Pharmacother. 2002;36(6):992–5.CrossRefPubMed
54.
Higginbotham EJ, Kilimanjaro HA, Wilensky JT, Batenhorst RL, Hermann D. The effect of caffeine on intraocular pressure in glaucoma patients. Ophthalmology. 1989;96(5):624–6.CrossRefPubMed
55.
Li M, Wang M, Guo W, Wang J, Sun X. The effect of caffeine on intraocular pressure: a systematic review and meta-analysis. Graefes Arch Clin Exp Ophthalmol. 2011;249(3):435–42.CrossRefPubMed
56.
Chandrasekaran S, Rochtchina E, Mitchell P. Effects of caffeine on intraocular pressure: the Blue Mountains Eye Study. J Glaucoma. 2005;14(6):504–7.CrossRefPubMed
57.
Kurata K, Fujimoto H, Tsukuda R, Suzuki T, Ando T, Tokuriki M. Aqueous humor dynamics in beagle dogs with caffeine-induced ocular hypertension. J Vet Med Sci. 1998;60(6):737–9.CrossRefPubMed
58.
Kurata K, Maeda M, Nishida E, et al. Relationship between caffeine-induced ocular hypertension and ultrastructure changes of non-pigmented ciliary epithelial cells in rats. J Toxicol Sci. 1997;22(5):447–54.CrossRefPubMed
59.
Kang JH, Willett WC, Rosner BA, Hankinson SE, Pasquale LR. Caffeine consumption and the risk of primary open-angle glaucoma: a prospective cohort study. Invest Ophthalmol Vis Sci. 2008;49(5):1924–31.CrossRefPubMedPubMedCentral
60.
61.
Pasquale LR, Wiggs JL, Willett WC, Kang JH. The relationship between caffeine and coffee consumption and exfoliation glaucoma or glaucoma suspect: a prospective study in two cohorts. Invest Ophthalmol Vis Sci. 2012;53(10):6427–33.CrossRefPubMedPubMedCentral
62.
Grubben MJ, Boers GH, Blom HJ, et al. Unfiltered coffee increases plasma homocysteine concentrations in healthy volunteers: a randomized trial. Am J Clin Nutr. 2000;71(2):480–4.CrossRefPubMed
63.
Urgert R, van Vliet T, Zock PL, Katan MB. Heavy coffee consumption and plasma homocysteine: a randomized controlled trial in healthy volunteers. Am J Clin Nutr. 2000;72(5):1107–10.CrossRefPubMed
64.
Bleich S, Roedl J, Von ahsen N, et al. Elevated homocysteine levels in aqueous humor of patients with pseudoexfoliation glaucoma. Am J Ophthalmol. 2004;138(1):162–4.CrossRefPubMed
65.
Wierzejska R. Tea and health—a review of the current state of knowledge. Przegl Epidemiol. 2014;68(3):501–6 (595-9).PubMed
66.
Milea D, Aung T. Flavonoids and glaucoma: revisiting therapies from the past. Graefes Arch Clin Exp Ophthalmol. 2015;253(11):1839–40.CrossRefPubMed
67.
Maher P, Hanneken A. Flavonoids protect retinal ganglion cells from oxidative stress-induced death. Invest Ophthalmol Vis Sci. 2005;46(12):4796–803.CrossRefPubMed
68.
Grassi D, Mulder TP, Draijer R, Desideri G, Molhuizen HO, Ferri C. Black tea consumption dose-dependently improves flow-mediated dilation in healthy males. J Hypertens. 2009;27(4):774–81.CrossRefPubMed
69.
Nash KM, Shah ZA. Current Perspectives on the beneficial role of Ginkgo biloba in neurological and cerebrovascular disorders. Integr Med Insights. 2015;10:1–9.CrossRefPubMedPubMedCentral
70.
Cybulska-Heinrich AK, Mozaffarieh M, Flammer J. Ginkgo biloba: an adjuvant therapy for progressive normal and high tension glaucoma. Mol Vis. 2012;18:390–402.PubMedPubMedCentral
71.
72.
Chung HS, Harris A, Kristinsson JK, Ciulla TA, Kagemann C, Ritch R. Ginkgo biloba extract increases ocular blood flow velocity. J Ocul Pharmacol Ther. 1999;15(3):233–40.CrossRefPubMed
73.
Hirooka K, Tokuda M, Miyamoto O, Itano T, Baba T, Shiraga F. The Ginkgo biloba extract (EGb 761) provides a neuroprotective effect on retinal ganglion cells in a rat model of chronic glaucoma. Curr Eye Res. 2004;28(3):153–7.CrossRefPubMed
74.
Eckert A, Keil U, Scherping I, Hauptmann S, Müller WE. Stabilization of mitochondrial membrane potential and improvement of neuronal energy metabolism by Ginkgo biloba extract EGb 761. Ann N Y Acad Sci. 2005;1056:474–85.CrossRefPubMed
75.
76.
Park JW, Kwon HJ, Chung WS, Kim CY, Seong GJ. Short-term effects of Ginkgo biloba extract on peripapillary retinal blood flow in normal tension glaucoma. Korean J Ophthalmol. 2011;25(5):323–8.CrossRefPubMedPubMedCentral
77.
Shim SH, Kim JM, Choi CY, Kim CY, Park KH. Ginkgo biloba extract and bilberry anthocyanins improve visual function in patients with normal tension glaucoma. J Med Food. 2012;15(9):818–23.CrossRefPubMedPubMedCentral
78.
Quaranta L, Bettelli S, Uva MG, Semeraro F, Turano R, Gandolfo E. Effect of Ginkgo biloba extract on preexisting visual field damage in normal tension glaucoma. Ophthalmology. 2003;110(2):359–62.CrossRefPubMed
79.
Guo X, Kong X, Huang R, et al. Effect of Ginkgo biloba on visual field and contrast sensitivity in Chinese patients with normal tension glaucoma: a randomized, crossover clinical trial. Invest Ophthalmol Vis Sci. 2014;55(1):110–6.CrossRefPubMed
80.
Coleman AL, Stone KL, Kodjebacheva G, et al. Glaucoma risk and the consumption of fruits and vegetables among older women in the study of osteoporotic fractures. Am J Ophthalmol. 2008;145(6):1081–9.CrossRefPubMed
81.
Emam WA, Zidan HE, Abdulhalim BE, Dabour SA, Ghali MA, Kamal AT. Endothelial nitric oxide synthase polymorphisms and susceptibility to high-tension primary open-angle glaucoma in an Egyptian cohort. Mol Vis. 2014;20:804–11.PubMedPubMedCentral
82.
Kang JH, Willett WC, Rosner BA, Buys E, Wiggs JL, Pasquale LR. Association of dietary nitrate intake with primary open-angle glaucoma: a prospective analysis from the nurses’ health study and health professionals follow-up study. JAMA Ophthalmol. 2016;134(3):294–303.CrossRefPubMedPubMedCentral
83.
Kerimi A, Williamson G. The cardiovascular benefits of dark chocolate. Vascul Pharmacol. 2015;71:11–5.CrossRefPubMed
84.
Heiss C, Kleinbongard P, Dejam A, et al. Acute consumption of flavanol-rich cocoa and the reversal of endothelial dysfunction in smokers. J Am Coll Cardiol. 2005;46(7):1276–83.CrossRefPubMed
85.
Desch S, Kobler D, Schmidt J, et al. Low vs. higher-dose dark chocolate and blood pressure in cardiovascular high-risk patients. Am J Hypertens. 2010;23(6):694–700.CrossRefPubMed
86.
87.
Terai N, Gedenk A, Spoerl E, Pillunat LE, Stodtmeister R. The short-term effect of flavonoid-rich dark chocolate on retinal vessel diameter in glaucoma patients and age-matched controls. Acta Ophthalmol. 2014;92(5):e341–5.CrossRefPubMed
88.
Jabbarpoor Bonyadi MH, Yazdani S, Saadat S. The ocular hypotensive effect of saffron extract in primary open angle glaucoma: a pilot study. BMC Compl Altern Med. 2014;14:399.CrossRef
89.
Maccarone R, Di Marco S, Bisti S. Saffron supplement maintains morphology and function after exposure to damaging light in mammalian retina. Invest Ophthalmol Vis Sci. 2008;49(3):1254–61.CrossRefPubMed
90.
Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001; 119(10):1417–36.CrossRefPubMedCentral
91.
Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. 2013; 309(19):2005–15.CrossRef
92.
Abu-Amero KK, Azad TA, Mousa A, Osman EA, Sultan T, Al-Obeidan SA. Total antioxidant level is correlated with intra-ocular pressure in patients with primary angle closure glaucoma. BMC Res Notes. 2014;7:163.CrossRefPubMedPubMedCentral
93.
Demirdögen BC, Ceylan OM, Işikoğlu S, Mumcuoğlu T, Erel O. Evaluation of oxidative stress and paraoxonase phenotypes in pseudoexfoliation syndrome and pseudoexfoliation glaucoma. Clin Lab. 2014;60(1):79–86.PubMed
94.
Dursun F, Vural Ozec A, Aydin H, et al. Total oxidative stress, paraoxonase and arylesterase levels at patients with pseudoexfoliation syndrome and pseudoexfoliative glaucoma. Int J Ophthalmol. 2015;8(5):985–90.PubMedPubMedCentral
95.
Abu-Amero KK, Kondkar AA, Mousa A, Osman EA, Al-Obeidan SA. Decreased total antioxidants in patients with primary open angle glaucoma. Curr Eye Res. 2013;38(9):959–64.CrossRefPubMed
96.
97.
Abu-Amero KK, Kondkar AA, Mousa A, Osman EA, Al-Obeidan SA. Decreased total antioxidants status in the plasma of patients with pseudoexfoliation glaucoma. Mol Vis. 2011;17:2769–75.PubMedPubMedCentral
98.
Beyazyıldız E, Cankaya AB, Beyazyıldız O, et al. Disturbed oxidant/antioxidant balance in aqueous humour of patients with exfoliation syndrome. Jpn J Ophthalmol. 2014;58(4):353–8.CrossRefPubMed
99.
Ergan E, Ozturk F, Beyazyildiz E, et al. Oxidant/antioxidant balance in the aqueous humor of patients with glaucoma. Int J Ophthalmol. 2016;9(2):249–52.PubMedPubMedCentral
100.
Wang SY, Singh K, Lin SC. Glaucoma and vitamins A, C, and E supplement intake and serum levels in a population-based sample of the United States. Eye (Lond). 2013;27(4):487–94.CrossRefPubMedPubMedCentral
101.
Garcia-Medina JJ, Garcia-Medina M, Garrido-Fernandez P, et al. A two-year follow-up of oral antioxidant supplementation in primary open-angle glaucoma: an open-label, randomized, controlled trial. Acta Ophthalmol. 2015;93(6):546–54.CrossRefPubMed
102.
Ren H, Magulike N, Ghebremeskel K, Crawford M. Primary open-angle glaucoma patients have reduced levels of blood docosahexaenoic and eicosapentaenoic acids. Prostaglandins Leukot Essent Fatty Acids. 2006;74(3):157–63.CrossRefPubMed
103.
de Arcelus MP, Toledo E, Martínez-González MÁ, Sayón-Orea C, Gea A, Moreno-Montañés J. Omega 3:6 ratio intake and incidence of glaucoma: the SUN cohort. Clin Nutr. 2014;33(6):1041–5.CrossRef
104.
Kang JH, Pasquale LR, Willett WC, et al. Dietary fat consumption and primary open-angle glaucoma. Am J Clin Nutr. 2004;79(5):755–64.CrossRefPubMed
Metadata
Title
The Role of Diet in Glaucoma: A Review of the Current Evidence
Authors
Adi M. Al Owaifeer
Abdulaziz A. Al Taisan
Publication date
01-06-2018
Publisher
Springer Healthcare
Published in
Ophthalmology and Therapy / Issue 1/2018
Print ISSN: 2193-8245
Electronic ISSN: 2193-6528
DOI
https://doi.org/10.1007/s40123-018-0120-3

Other articles of this Issue 1/2018

Ophthalmology and Therapy 1/2018 Go to the issue

Case Report

A Case Report of Conservative Management for a Roller-Coaster-Related Vitreous Haemorrhage

Case Report

Case Report: Scleral Metastasis of Esophageal Squamous Cell Carcinoma

Original Research

Real-World Cost Savings Demonstrated by Switching Patients with Refractory Diabetic Macular Edema to Intravitreal Fluocinolone Acetonide (Iluvien): A Retrospective Cost Analysis Study

Original Research

Choriocapillaris Vascular Density Changes in Patients with Drusen: Cross-Sectional Study Based on Optical Coherence Tomography Angiography Findings

Case Series

Aflibercept in Diabetic Macular Oedema Previously Refractory to Standard Intravitreal Therapy: An Irish Retrospective Study

Original Research

Eplerenone Versus Observation in the Treatment of Acute Central Serous Chorioretinopathy: A Retrospective Controlled Study
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits